Nimbus Therapeutics

OverviewSuggest Edit

Nimbus Therapeutics is a biotechnology company which operates an application of computational chemistry to design treatments for substantial and underserved human diseases. The Company aims to disrupt known drivers of serious diseases, including metabolic disease, cancer, and immune-inflammatory disorders.

TypePrivate
Founded2009
HQCambridge, MA, US
Websitenimbustx.com

Latest Updates

Employees (est.) (Sept 2021)60
Cybersecurity ratingAMore

Key People/Management at Nimbus Therapeutics

George P. Vlasuk

George P. Vlasuk

Director
Scott Edmondson

Scott Edmondson

Senior Vice President, Head of Chemistry
Erin Cowhig

Erin Cowhig

Chief People Officer
Jeb Keiper

Jeb Keiper

Chief Executive Officer, Director
Abbas Kazimi

Abbas Kazimi

Chief Business Officer
Mark Iwicki

Mark Iwicki

Director
Show more

Nimbus Therapeutics Office Locations

Nimbus Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
130 Prospect St #301Cambridge
Show all (1)

Nimbus Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2009

Nimbus Therapeutics total Funding

$242 m

Nimbus Therapeutics latest funding size

$105 m

Time since last funding

3 months ago

Nimbus Therapeutics investors

Nimbus Therapeutics's latest funding round in July 2021 was reported to be $105 m. In total, Nimbus Therapeutics has raised $242 m
Show all financial metrics

Nimbus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Nimbus Therapeutics Online and Social Media Presence

Embed Graph

Nimbus Therapeutics Blogs

Nimbus Therapeutics Appoints Ian Sanderson, MBA, as Chief Financial Officer

CAMBRIDGE, Mass. – September 21, 2021 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Ian Sanderson, MBA, as Chief Financial Officer. He succeeds Holly Whittemore, CPA, who will…

Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis

CAMBRIDGE, Mass. – September 14, 2021 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced dosing of patients in the Phase 2b study of the company’s oral allosteric TYK2 inhibitor. The study will asses…

Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets

CAMBRIDGE, Mass. – August 12, 2021 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the extension of its collaboration with Schrödinger, Inc. to discover and design small molecule therapeutics for …

Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs

– Multiple Phase 2 studies of allosteric TYK2 inhibitor in 2021 and 2022 will investigate ‘pipeline-in-a-product’ potential – – Financing will also support first-in-human trial of HPK1 inhibitor and advancement of preclinical pipeline – – Led by BVF Partners L.P., round included participation from n…

Nimbus Therapeutics Appoints Anne McGeorge to its Board of Directors

CAMBRIDGE, Mass. – May 10th, 2021 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced it has appointed Anne McGeorge, M.S., CPA, to its Board of Directors, and as Audit Committee Chair. Ms. McGeorge is a se…

Nimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical Testing

– Key hires in clinical and CMC augment Nimbus’ in-house capabilities as a development-stage biotech – CAMBRIDGE, Mass. – April 21, 2021 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the expansion of …
Show more

Nimbus Therapeutics Frequently Asked Questions

  • When was Nimbus Therapeutics founded?

    Nimbus Therapeutics was founded in 2009.

  • Who are Nimbus Therapeutics key executives?

    Nimbus Therapeutics's key executives are George P. Vlasuk, Scott Edmondson and Erin Cowhig.

  • How many employees does Nimbus Therapeutics have?

    Nimbus Therapeutics has 60 employees.

  • Who are Nimbus Therapeutics competitors?

    Competitors of Nimbus Therapeutics include Codiak Biosciences, Aligos Therapeutics and AstraZeneca.

  • Where is Nimbus Therapeutics headquarters?

    Nimbus Therapeutics headquarters is located at 130 Prospect St #301Cambridge, Cambridge.

  • Where are Nimbus Therapeutics offices?

    Nimbus Therapeutics has an office in Cambridge.

  • How many offices does Nimbus Therapeutics have?

    Nimbus Therapeutics has 1 office.